Does a plateau mean semaglutide stopped working?
Not necessarily. In STEP 5, the average weight curve on semaglutide flattened around week 60 and remained broadly stable through week 104. Maintaining a lower weight is different from never responding. But a study average cannot determine why your own weight is steady, whether the current plan meets your goals, or what should change next.[1]
The practical next step is a review with your clinician, not an improvised dose increase, a second weight-loss medicine or an extreme food restriction. Bring the trend and your actual concern: perhaps weight has been stable for a while, appetite feels different, treatment has been interrupted, or the original goal now seems out of reach. These are different questions even when the scale reading looks similar.
A steady month can feel disappointing after a period of visible change. It is still useful information. The aim of follow-up is to understand the current phase and agree on what matters next, rather than to turn every weigh-in into a verdict on effort or success.
What the two-year trial actually measured
STEP 5 randomized 304 adults without diabetes to weekly semaglutide 2.4 mg or placebo, alongside behavioral support, for 104 weeks. Mean estimated weight change at two years was −15.2% with semaglutide and −2.6% with placebo. The trial was funded by Novo Nordisk. It studied a particular treatment and population, not every semaglutide formulation or an individualized plateau rescue strategy.[1]
Three phases to distinguish
The chart is a group summary, not a schedule you are expected to follow. Someone can reach a stable period earlier or later, and the average does not identify the right goal for an individual. Nor does the trial establish that changing treatment at week 60 would improve outcomes. It observed a longer course; it did not randomize people at a plateau to competing next steps.
When reading a comparison online, check whether the author is describing a treatment group, an individual story or a proposed strategy. Those kinds of evidence answer different questions. An anecdote about renewed weight loss after a change cannot show that the change caused the result or that it would be appropriate for you.
A steady weight during treatment is a different question from weight regain after stopping semaglutide.
A plateau is not the same as early nonresponse
| What you notice | What to bring to the conversation |
|---|---|
| Little change since treatment began | Ask how the clinician is assessing response in the context of your treatment history. |
| Loss followed by a sustained stable period | Ask whether maintenance currently fits your health goals and the overall benefit. |
| Weight rising after an interruption | Explain access gaps and ask for a prescriber-led continuity review. |
| A few isolated higher readings | Bring the broader record rather than treating one reading as the whole trend. |
Use the measurements you already have, including their dates. If you and the clinician agree that additional monitoring would help, ask what is useful and how often. A more elaborate spreadsheet is not automatically a better clinical record. It should answer a question you both understand, rather than encourage constant checking with no agreed interpretation.
Write down major changes in your routine or access alongside the weight record: a missed appointment, delayed refill, illness, travel or a new medicine. Report these plainly, without trying to decide in advance which one explains the pattern. That lets the clinician review the timeline instead of reconstructing it from scattered messages and pharmacy receipts.
Why maintaining progress still deserves care
In an NIDDK interview, obesity specialist Jamy Ard describes biological adaptations after weight loss, including increased appetite and reduced energy requirements, and frames maintenance as an active part of care. The discussion concerns longer-term weight management, especially in people with diabetes; it is not a semaglutide-specific instruction for breaking a plateau.[2]
For your visit, separate “I want to lose more” from “I am worried the treatment no longer has value.” Both are reasonable topics, but they invite different discussions. Ask the clinician which outcomes are relevant to you, what has changed since starting, and how they weigh benefit against side effects, cost and the effort of ongoing care. Do not assume there is one target that every person should pursue.
It may help to ask for the review in ordinary language: “What are we trying to achieve in the next few months, and what would make us reconsider?” That question leaves room for a clinical decision without asking you to design the treatment yourself. Make sure the answer includes when you will speak again and how to report a change in between.
Review the practical obstacles without blame
Bring the actual access problem if there is one. A delayed shipment, unclear renewal process or unaffordable bill is worth describing directly. Ask the provider to separate what the clinical team can decide from what billing or insurance staff must resolve. A vague instruction to “stay consistent” is difficult to use if the service has not explained how the next prescription will reach you.
Our semaglutide withdrawal explainer discusses what happened after treatment and structured support ended in a different study. It should not be used to predict a plateau during continuing treatment. The tirzepatide maintenance study also asks a different question; it does not establish that switching medicines is the right response to your steady scale.
If side effects are shaping your routine, include them in the review. The nausea guide can help organize that message. Avoid presenting an ideal week while leaving out the difficult days; the treatment plan needs to fit the life you are actually living. At the same time, you do not need to account for every meal before you are entitled to follow-up.
Leave with a plan, not a promise
A useful review ends with an agreed goal, the next contact point and a clear division of responsibilities. Ask which changes would mean returning earlier. If the plan involves another professional, clarify who makes the referral and how the findings reach the prescriber. A promise of continued weight loss is less useful than knowing how decisions will be made if the pattern changes.
Compare documented follow-up in the semaglutide provider guide and the Form Health review. Use the care-cost planner to look at a realistic ongoing period, including known appointment and medication costs. These tools organize service questions; the STEP 5 results do not validate any provider, guarantee another phase of loss or set a personal treatment target.